STIFEL 2026 HEALTHCARE CONFERENCE - SYNDAX PHARMACEUTICALS INC

Explicit Guidance:

• No specific quantitative financial guidance (revenue, earnings, margins, or cash flow) for future periods was provided in the transcript.
• Margins: Management confirmed margins are currently in the 30–35% range and expect this to remain stable for the "foreseeable future," noting an improvement from the prior 25–30% range.
• Profitability: The company is "pacing very well" with disciplined spending, expressing an aspiration to reach profitability "soon," though no specific date was defined.
• Revenue Drivers: Anticipated tailwinds from extending patient duration of therapy (maintenance) are expected to significantly impact revenue beginning in 2027, particularly for the KMT2A and NPM1 segments.

Business-Segment Outlook:

• Revumenib (Revuforge) / NPM1:
  • Transplant/Maintenance Dynamics: Approximately 40% of NPM1 patients are now proceeding to transplant, with 50–60% returning for maintenance therapy, a trend expected to persist and grow.
  • Patient Growth: New patient starts are expected to continue growing quarter-over-quarter as the company expands into new mutations (e.g., NUP98).
  • Revenue Timing: The financial benefit of durable maintenance therapy (patients returning post-transplant) is projected to become a meaningful revenue driver in 2027.
• Niktimab (Nick Timbo):
  • Market Penetration: Currently holds ~33% market share in the third-line-plus GVHD space (approx. 6,000 patients); targets expansion toward the total addressable market of 15,000–17,000 patients.
  • Combination Strategy: Data for the Ruxolitinib combination (Phase 2) is expected to be read out in Q1 of next year; positive data could enable frontline use and compendium listing to avoid steroids.
  • Pivotal Trial: A pivotal frontline trial (steroid vs. combination) is scheduled to read out in Q1 2028.
  • Commercial Contribution: Revuforge contributed $22.6 million in net contribution to the company in the reported quarter.

Market and Competitive Outlook:

• Competitive Landscape (Menin Inhibitors): Management asserts a "dominant position" in the relapsed/refractory market with a 3-year lead over competitors (e.g., J&J). They anticipate the field will shift decisively toward combination therapies rather than monotherapy.
• Frontline Trials: Differentiates from competitors by running two separate, smaller Phase 3 studies (one ~30% smaller than competitor studies requiring ~1,000 patients) to target unfit (EVOLVE-2) and fit (Hovon) populations with distinct outcomes.
• EGFR Market: The novel EGFR inhibitor targets a different binding pocket (allosteric vs. catalytic) to address patients refractory to Osimertinib, specifically those with CNS metastases, positioning it for later-line combination use rather than direct front-line competition.
• Myelofibrosis (MF): Next-gen menin inhibitor (Rev 62122) aims to capture patients suboptimal to JAK inhibitors, with development accelerated by proof-of-principle data from Revumenib in MF.

Macro / Industry Outlook:

• Clinical Paradigm Shift: The industry is moving from monotherapy to combination regimens and earlier intervention (e.g., MRD relapse), reducing the relevance of standalone monotherapy data.
• Treatment Lifecycle: Increased focus on transplant optimization and maintenance therapy as key drivers for long-term patient survival and commercial value.

Strategic Initiatives:

• Pipeline Launches:
  • EGFR Inhibitor: IND submission expected by year-end; clinical trials to commence in the next year (2025). Anticipated to show early monotherapy activity.
  • Next-Gen Menin (Rev 62122): Proof-of-principle trials in Myelofibrosis using Revumenib expected to report data in 2027; IND filing for Rev 62122 also targeted for 2027.
  • Ravens Study: Ongoing to test Revumenib as a bridge to transplant for fit patients with KMT2A, avoiding intensive chemotherapy morbidity.
• Pivotal Studies:
  • EVOLVE-2 & Hovon: Dual primary endpoints to allow for accelerated approval; enrollment is active across China, Japan, Asia, Latin America, Europe, and the US.
  • Maintain Study: Prospective randomized trial with Dana-Farber to isolate maintenance contribution post-transplant.
• M&A/BD: Strategy remains active; the company acquired all assets (except next-gen menin) via business development and will continue to look for impactful opportunities, though no specific targets were named.

Risks and Headwinds to Outlook:

• Data Uncertainty: Future success in frontline and combination settings depends on the positive readout of the Q1 (next year) Phase 2 Ruxolitinib combo data and the Q1 2028 pivotal trial.
• Adverse Event Management: Potent menin inhibitors carry risks of on-target toxicities, including differentiation syndrome and cytopenias (specifically thrombocytopenia), which may require dose titration and careful management, potentially impacting patient retention.
• Enrollment Challenges: The highly competitive space may present challenges in patient enrollment for Phase 3 studies, though the company believes its streamlined design mitigates this relative to competitors.
• Variable Timelines: Patient return rates to maintenance therapy post-transplant vary, creating some volatility in quarter-to-quarter revenue visibility.

Management Tone on the Future:

• Confidence Level: Highly confident and "very excited." Management describes the company as being in a "great position" and at a "pivotal time" regarding the transition from commercial growth to clinical expansion.
• Strategic Narrative: Emphasizes "disciplined spending," "nimble" trial designs, and a clear transition from early-stage commercial growth to a broader, more profitable franchise driven by maintenance and frontline indications.
• Competitive Stance: Dismissive of competitor headline data (J&J), characterizing it as less relevant due to differing patient populations and the industry's shift to combination therapies where Revumenib leads.

Miscellaneous:

• Upcoming Catalysts: Significant data presentations scheduled for the ASH conference (covering transplant maintenance, bridge-to-transplant, and MRD intervention) and a Q1 conference for GVHD combo data.
• Operational Update: Enrollment is "moving quickly" with hundreds of active sites globally for Phase 3 studies.